KalVista Says UK MHRA Awarded Innovation Passport For Sebetralstat, An Investigational Novel, Oral Plasma Kallikrein Inhibitor For On-demand Treatment Of Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharmaceuticals announced that the UK's MHRA has awarded an Innovation Passport for Sebetralstat, a novel oral treatment for Hereditary Angioedema. This is the initial step in the ILAP, aimed at accelerating market access for innovative medicines.
February 20, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
KalVista Pharmaceuticals receives Innovation Passport from UK's MHRA for Sebetralstat, a novel treatment for Hereditary Angioedema, marking a significant regulatory milestone.
The Innovation Passport is a significant regulatory milestone that can significantly accelerate the time to market for Sebetralstat. This development is likely to be viewed positively by investors, as it represents progress in the drug's development pathway and potential for early market access in the UK, which could lead to increased investor confidence and potential stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90